Restore Mind Medicine

MM-110 Preclinical Safety Studies Sep 2023 Dec 2023 Review of MM-110 data in Phase I study (Low Priority) Review timeline for: Performing pre-clinical safety studies, Extending Phase I to get a 30-day dose, and the timing for NDA. Commercial analysis of market opportunities in opioid addiction treatment. 67

View entire presentation